Rentschler Biopharma to build
new cell and gene therapy capabilities in the UK
Leading German CDMO for biopharmaceuticals, Rentschler Biopharma will establish their manufacturing capability in ATMPs, including Adeno-Assiociated Virus (AAV) vectors for clinical trial supply at the Cell and Gene Therapy (CGT) Catapult facility site in Stevenage. Under the terms of the agreement, Rentschler Biopharma will make a significant investment at the site over the next five years to set up their manufacturing capabilities, benefitting from the expertise and collaborative model provided by the CGT Catapult.
UK enhances the attractiveness of its cell and gene therapy ecosystem
The company’s investment is expected to make a major contribution to meeting the demand from UK and international researchers for suitable manufacturing capability. This development will further strengthen the UK ecosystem through the addition of Rentschler Biopharma’s more than 40 years of experience and solid reputation in the development and manufacturing of biologics for both clinical and commercial supply. This investment in the UK cell and gene therapy industry is expected to further accelerate the development of the vital infrastructure and skilled jobs needed to meet the rising demand for manufacturing capacity in the UK and globally, as well as streamline the supply chain for these advanced therapies. Currently, 27% of European ATMP companies are operating in the UK, and there are more than 90 advanced therapy developers. The last year has also seen a 50% increase in the number of ATMP clinical trials being run in the UK, accounting for 12% of global ATMP clinical trials, and these numbers are predicted to increase further.
Rentschler Biopharm will leverage the CGT Catapult’s expertise in ATMP manufacturing setup and technology development, as well as the cell and gene therapy cluster and ecosystem that has developed around Stevenage and across the UK. Dr. Frank Mathias, CEO of Rentschler Biopharma said: “We are excited to take this next big step in our evolution and address the growing industry demand for ATMP manufacturing capacity and viral vector supply. With the largest industry cluster for cell and gene therapies outside the US, the UK is an ideal location for us to establish our Center of Excellence for cell and gene therapy. We look forward to working with the CGT Catapult as we invest in this growing field. They are well established in this important market, enabling us to immediately tap into the organisation’s network and utilise the UK’s strong expertise and supply chain in cell and gene therapy manufacturing.” The CGT Catapult manufacturing centre has been already backed by over £75m of funding, including investment from the UK Government’s Industrial Strategy Challenge Fund, the Department for Business, Energy and Industrial Strategy, Innovate UK and from the European Regional Development Fund. Since it was announced, there has been over £1.1bn of investment in the ATMP industry in its vicinity.
Anne-Lise Berthier (11/02/2021)